 |
Indication & Dosage |
| |
| |
| Oral |
| MODERATE TO SEVERE VASOMOTOR SYMPTOMS ASSOCIATED WITH MENOPAUSE |
| Adult:
0.45 mg/day; may increase up to 1.25 mg/day; attempt to discontinue medication at 3-6-mth intervals. |
| |
| Oral |
| VULVULAR AND VAG ATROPHY |
| Adult:
0.3 mg/day. |
| |
| Oral |
| FEMALE HYPOGONADISM |
| Adult:
0.3-0.625 mg/day given cyclically, may titrate dose in 6-12-mth intervals; add progestin treatment to maintain bone mineral density once skeletal maturity is achieved. |
| |
| Oral |
| FEMALE CASTRATION OR PRIMARY OVARIAN FAILURE |
| Adult:
1.25 mg/day given cyclically; adjust according to patient response. For maintenance, adjust to the lowest effective dose. |
| |
| Oral |
| PALLIATIVE TREATMENT OF PROSTATIC CARCINOMA |
| Adult:
1.25-2.5 mg 3 times/day. |
| |
| Oral |
| OSTEOPOROSIS PROPHYLAXIS IN POSTMENOPAUSAL WOMEN |
| Adult:
Initial: 0.3 mg/day, cyclically or daily, depending on patient's condition. Adjust dose based on bone mineral density and clinical response. Lowest effective dose should be used. |
| |
| Parenteral |
| ABNORMAL UTERINE BLEEDING |
| Adult:
25 mg via IV/IM admin, may repeat in 6-12 hr if needed. Treatment should be followed by a low-dose oral contraceptive. |
|
| |
|
| Administration |
May be taken with or without food. |
| |
|
| Precautions |
Asthma, epilepsy, migraine; heart or kidney dysfunction; CV disease; cerebrovascular disorders; diabetes, hypercalcaemia; gall bladder disease; porphyria. Childn. Lactation. |
| |
|
Potentially Life-threatening
Adverse Drug Reactions |
Abnormal bleeding; vomiting, nausea; tender breasts, wt gain, fluid retention; headache, depression. Males: Gynaecomastia, impotence. |
| |
|
| Adverse Drug Reactions |
Unopposed replacement therapy in postmenopausal women associated with increased risk of endometrial and breast cancer. |
| |
|
| Interactions |
May reduce the efficacy of anticoagulants. Rifampicin, barbiturates increase rate of metabolism. |
| |
|
|
|
